EHA 2024 Highlights: Overcoming Challenges with Bispecific Antibodies in RRMM

The key secondary end point of overall survival (OS) was met in the DREAMM-7 trial of belantamab mafodotin (Blenrep; GSK) for the treatment of patients with relapsed/refractory multiple myeloma (R/R MM).

Don M. Benson, MD, PhD, has cared for patients at James Cancer Hospital in Ohio for 22 years, where he and his team see approximately 10,000 patient visits each year.

Multiple myeloma is the second most common hematologic malignancy, but there is a treatment gap for patients with disease progression following standard-of-care therapies that include immunomodulatory agents, proteasome inhibitors, and anti-CD38 antibodies.

Allowing patients to stay in their homes to receive bispecific antibodies can make the whole cancer journey easier, explained Courtney VanHouzen, PharmD, of Cowell Family Cancer Center, Munson Healthcare.

Outcomes of interest in this study were time from diagnosis to initial prescription fill for an oral multiple myeloma (MM) medication and time from initial diagnosis to receipt of any treatment for MM.